Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis

Nephrology Dialysis Transplantation

Volumn 28, Issue 11, 2013, Pages 2735-2744

  Panizo, Sara ^a   Barrio Vázquez, Sara ^a   Naves Díaz, Manuel ^a   Carrillo López, Natalia ^a   Rodríguez, Isabel ^a   Fernández Vázquez, Amalia ^b   Valdivielso, Jose M ^c   Thadhani, Ravi ^d   Cannata Andía, Jorge B ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b Centro Medico de Asturias   (Spain)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CKD; LVH; Myocardial fibrosis; VDRAs

Indexed keywords

ALFACALCIDOL; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCITRIOL; COLLAGEN TYPE 1; INTERSTITIAL COLLAGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PARICALCITOL; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; MALE; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; UREMIA;

CKD; LVH; MYOCARDIAL FIBROSIS; VDRAS;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CARDIOMYOPATHIES; ERGOCALCIFEROLS; FIBROSIS; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MAP KINASE SIGNALING SYSTEM; NATRIURETIC PEPTIDE, BRAIN; PHOSPHORYLATION; RATS; RATS, WISTAR; RECEPTORS, CALCITRIOL;

EID: 84890054493     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft268     Document Type: Article

References (52)

1. Briet M, Pierre B, Laurent S et al. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 2012; 82: 388-400
2. Cerasola G, Nardi E, Palermo A et al. Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review. J Nephrol 2011; 24: 1-10
3. McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004; 15: 1640-1647
4. Park M, Hsu CY, Li Y et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol 2012; 23: 1725-1734
5. Nitta K, Iimuro S, Imai E et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease. Clin Exp Nephrol 2013 [Epub ahead of print]
6. Amann K, Ritz E, Wiest G et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994; 4: 1814-1819
7. London G. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant 2001; 16: 3-6
8. Amann K, Kronenberg G, Gehlen F et al. Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplant 1998; 13: 1958-1966
9. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569-582
10. Cozzolino M, Brandenburg V. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the 'U'. Clin Nephrol 2009; 71: 593-601
11. Pilz S, Marz W, Wellnitz B et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008; 93: 3927-3935
12. Poole KE, Loveridge N, Barker PJ et al. Reduced vitamin D in acute stroke. Stroke 2006; 37: 243-245
13. Naves-Diaz M, Cabezas-Rodriguez I, Barrio-Vazquez S et al. Low calcidiol levels and risk of progression of aortic calcification. Osteoporos Int 2011; 23: 1177-1182
14. Tamez H, Zoccali C, Packham D et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 2012; 164: 902-909 e2
15. Lau WL, Leaf EM, Hu MC et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012; 82: 1261-1270
16. Arenas MD, Alvarez-Ude F, Gil MT et al. Application of NKF-K/ DOQI Clinical Practice Guidelines for bone metabolism and disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units. Nephrol Dial Transplant 2006; 21: 1663-1668
17. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy- cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143
18. Nigwekar SU, Thadhani RI. Shining light on vitamin D trials in chronic kidney disease. Kidney Int 2013; 83: 198-200
19. Koleganova N, Piecha G, Ritz E et al. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 2009; 24: 778-787
20. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-524
21. Wu J, Garami M, Cheng T et al. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-1588
22. Li JM, Poolman RA, Brooks G. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol 1998; 275: H814-H822
23. Naves-Diaz M, Carrillo-Lopez N, Rodriguez-Rodriguez A et al. Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency. Menopause 2010; 17: 766-771
24. Cardus A, Panizo S, Parisi E et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-866
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001; 25: 402-408
26. Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A et al. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol 2009; 20: 2009-2017
27. Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport. J Lab Clin Med 2002; 139: 279-284
28. Shiizaki K, Hatamura I, Negi S et al. Highly concentrated calcitriol and its analogues induce apoptosis of parathyroid cells and regression of the hyperplastic gland-study in rats. Nephrol Dial Transplant 2008; 23: 1529-1536
29. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-1721
30. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-1284
31. Arenas MD, Muray S, Amoedo ML et al. A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis. Nefrologia 2006; 26: 226-233
32. Guerrero F, Montes de Oca A, Aguilera-Tejero E et al. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2012; 27: 2206-2212
33. Mizobuchi M, Morrissey J, Finch JL et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806
34. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238
35. Nakane M, Ma J, Ruan X et al. Mechanistic analysis of VDRmediated renin suppression. Nephron Physiol 2007; 107: p35-p44
36. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
37. Touchberry CD, Green TM, Tchikrizov V et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab 2013; 304: E863-E873
38. Covic A, Voroneanu L, Goldsmith D. The effects of vitamin D therapy on left ventricular structure and function-are these the underlying explanations for improved CKD patient survival? Nephron Clin Pract 2010; 116: c187-c195
39. Mizobuchi M, Nakamura H, Tokumoto M et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010; 121: 188-192
40. Selvetella G, Hirsch E, Notte A et al. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 2004; 63: 373-380
41. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007; 116: 1413-1423
42. Rubinfeld H, Seger R. The ERK cascade: a prototype of MAPK signaling. Mol Biotechnol 2005; 31: 151-174
43. Huebert RC, Li Q, Adhikari N et al. Identification and regulation of sprouty1, a negative inhibitor of the ERK cascade, in the human heart. Physiol Genomics 2004; 18: 284-289
44. Lin X, Jo H, Ishii TM et al. Controlled release of matrix metalloproteinase-1 plasmid DNA prevents left ventricular remodeling in chronic myocardial infarction of rats. Circ J 2009; 73: 2315-2321
45. Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002; 39: 258-263
46. Wilson R, Zhang P, Smyth M et al. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy. Curr Med Res Opin 2009; 25: 3021-3028
47. Miguel-Carrasco JL, Baltanas A, Cebrian C et al. Blockade of TGF-beta 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats. Oxid Med Cell Longev 2012; 2012: 726940
48. He W, Kang YS, Dai C et al. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011; 22: 90-103
49. Meems LM, Cannon MV, Mahmud H et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol 2012; 132: 282-289
50. Fedele F, Frati G, Biondi-Zoccai G. Questioning the validity of a recent randomized trial on paricalcitol in patients with echocardiographic evidence of cardiac hypertrophy. Int J Cardiol 2012, [Epub ahead of print]
51. Thadhani R, Appelbaum E, Pritchett Y et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684
52. Tripepi G, Mattace-Raso F, Mallamaci F et al. Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease. Hypertension 2009; 54: 818-824